Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 9:10 a.m. ET. CEO Michael Goettler and CFO Sanjeev Narula will discuss the company and answer questions. A live webcast will be available at investor.viatris.com, with an archived version accessible later. Formed in November 2020 from Mylan and Pfizer's Upjohn business, Viatris serves over 165 countries and offers a diverse portfolio of over 1,400 approved medicines.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on May 11, 2021, at 8 a.m. ET. President Rajiv Malik and CFO Sanjeev Narula will address questions regarding the company. Interested parties can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020, aims to provide global access to a diverse portfolio of over 1,400 medicines targeting various health conditions, supporting sustainable healthcare.
Viatris Inc. (NASDAQ: VTRS) will release its first quarter 2021 financial results on May 10, 2021, prior to the U.S. market opening. A webcast will follow at 10 a.m. ET to discuss these results, accessible at investor.viatris.com or via phone at 855.493.3607. Viatris formed in November 2020, merging Mylan and Pfizer's Upjohn. The company aims to improve global health access with a portfolio of over 1,400 approved molecules and operates in over 165 countries.
On March 8, 2021, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery announced the FDA granted tentative approval for the first generic version of Symbicort, budesonide/formoterol fumarate dihydrate. This approval, however, comes amid ongoing patent litigation with AstraZeneca, preventing immediate commercial launch. Despite significant U.S. sales of Symbicort, Viatris has not projected any revenue from this product for 2021. This milestone reflects the partnership's strength and Viatris’ commitment to advancing access to respiratory treatments.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 p.m. ET. Key executives including CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will address questions regarding the company. A live webcast can be accessed at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020 from Mylan and Pfizer's Upjohn business, aims to enhance global healthcare access.
On March 1, 2021, Viatris Inc. (NASDAQ: VTRS) hosted its inaugural investor day, presenting its unique healthcare model aimed at enhancing shareholder value. CEO Michael Goettler emphasized a commitment to sustainability, financial stability, and growth through their Global Healthcare Gateway. Viatris expects 2021 to be a trough year, projecting $1 billion in synergies within three years and a dividend initiation in Q2 2021. The company plans to reduce $6.5 billion in debt by the end of 2023 and focus on improving free cash flow while building a diverse portfolio for global access to medicines.
Viatris announced its 2021 financial guidance, projecting revenues between $17.2 billion and $17.8 billion and adjusted EBITDA between $6.0 billion and $6.4 billion. The company aims for free cash flow of $2.0 billion to $2.3 billion, with a commitment to de-leveraging and enhancing cash flows. Viatris will initiate a dividend of at least 25% of free cash flow, expecting to pay approximately $400 million in dividends in 2021. A long-term leverage target of 2.5x is also set, with $6.5 billion in debt repayment anticipated by the end of 2023.
Viatris Inc. (NASDAQ: VTRS) announced a conference call for February 22, 2021, at 8 a.m. ET to discuss its 2021 financial guidance. The call can be accessed at (855) 493-3607 (US) or (346) 354-0950 (international) with ID# 3235536, as well as via their website. Additionally, Viatris will hold its first virtual Investor Day on March 1, 2021, starting at 8:30 a.m. ET, featuring key executives who will detail strategies for maximizing shareholder returns. The company emerged from the combination of Mylan and Pfizer's Upjohn business in November 2020.
Viatris Inc. (NASDAQ: VTRS) announced a favorable ruling from the U.S. District Court for the District of Kansas, granting summary judgment in favor of Mylan in its lawsuit against Sanofi regarding EpiPen products. The judgment dismisses Sanofi's allegations of anticompetitive practices and supports Mylan's defense against these claims. Over the past three years, Sanofi has unjustly sought damages and blamed Mylan for its own marketing failures with Auvi-Q, a product that Sanofi previously recalled due to dosage inaccuracies.
